Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved total revenue of 2.058 billion yuan in 2025, representing a year-on-year increase of 6.5%. The revenue from drug sales surged by 949.8% to 543 million yuan, primarily due to the approval of new indications for its main products [8] - The commercialization of the core product, Sac-TMT, is progressing smoothly, with expectations for rapid growth as it covers over 30 provinces and 2,000 hospitals in China. Key indications have been included in the national medical insurance directory [8] - The company has a robust pipeline with multiple clinical trials ongoing, including four approved indications for Sac-TMT and several others in advanced stages. The ADC platform is also showing significant progress with multiple candidates entering clinical phases [8] Financial Summary - Total revenue projections for the company are 3.56 billion yuan in 2026, 5.89 billion yuan in 2027, and 7.66 billion yuan in 2028, indicating substantial growth rates of 72.99%, 65.56%, and 30.03% respectively [1][9] - The net profit is expected to turn positive by 2027, with a forecasted net profit of 649.8 million yuan, and further increasing to 1.62 billion yuan by 2028 [1][9] - The company maintains a strong cash position, with cash and financial assets exceeding 4.542 billion yuan, reflecting a 48% increase [8]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 576.70 [5][4] Core Insights - The company reported a revenue of RMB 2.058 billion for 2025, representing a year-on-year growth of 6.5%, but incurred a loss of RMB 381.97 million [1] - The growth in revenue is attributed to the continued ramp-up of SKB264 sales and BD/R&D service income [1] - The company is expected to see significant growth in SKB264 sales, particularly with new indications entering the insurance reimbursement list [2] - The overseas phase III clinical data for SKB264 is anticipated to mature by the end of 2026, potentially contributing significantly to revenue [2] - The company is also optimistic about other pipeline products, particularly SKB571, which is expected to show strong efficacy with low systemic toxicity [3] Financial Projections - Revenue projections for 2026, 2027, and 2028 are RMB 2.702 billion, RMB 5.868 billion, and RMB 8.834 billion respectively, with significant growth rates expected [4][8] - The company is projected to turn profitable in 2027, with an estimated net profit of RMB 1.087 billion [8] - The DCF valuation method estimates the company's market value at HKD 134.5 billion [9]

Investment Rating - The report maintains a "BUY" rating for Kelun-Biotech, indicating a potential return of over 15% over the next 12 months [3][14]. Core Insights - Kelun-Biotech is transitioning from a clinical-stage biotech to a biopharmaceutical company, with 2025 marked as its inaugural year of commercialization, supported by four approved products and a strong revenue trajectory [1]. - The company reported total revenue of RMB2.06 billion in 2025, reflecting a year-on-year growth of 6.5%, with pharmaceutical product sales contributing RMB543 million [1][2]. - The inclusion of three core assets (Sac-TMT, A167, and A140) in the National Reimbursement Drug List (NRDL) effective January 2026 is expected to drive volume growth in 2026 [1]. - Despite a widened net loss of RMB382 million in 2025, the company's financial position remains robust, with RMB4.6 billion in cash and financial assets as of the end of 2025 [1]. Financial Summary - Revenue projections for FY26E are RMB2.127 billion, with expected growth of 3.4% year-on-year, and projected revenue for FY28E is RMB5.866 billion, reflecting a significant growth of 113.6% [2][11]. - The net profit is projected to be a loss of RMB689.7 million in FY26E, improving to a profit of RMB703.6 million by FY28E [2][11]. - The report indicates a gross profit margin improvement from 71.9% in FY25A to 81.6% in FY28E [12]. Share Performance and Valuation - The target price for Kelun-Biotech is set at HK$507.11, representing a 20.5% upside from the current price of HK$421.00 [3]. - The market capitalization of the company is approximately HK$98.17 billion [3]. - The DCF valuation per share is estimated at RMB446.25, equivalent to HK$507.11, based on a WACC of 8.69% and a terminal growth rate of 3.5% [7].

Investment Rating - The report maintains an "Outperform" rating for Sichuan Kelun-Biotech [2][9]. Core Insights - The company achieved a revenue of CNY 2.06 billion in FY25, reflecting a year-on-year growth of 6.5%. Drug sales revenue was CNY 540 million, while licensing and collaboration income decreased by 20% to CNY 1.50 billion. The net loss for the year was CNY 380 million, compared to a loss of CNY 270 million in FY24 [3][16]. - Several products have been successfully commercialized in China, including sac-TMT, tagitanlimab, cetuximab N01, and trastuzumab botidotin, with the first three included in the National Reimbursement Drug List (NRDL) [4][17]. - The company is progressing with multiple clinical trials, including 17 global Phase 3 trials for sac-TMT, with data readouts expected to begin in 2027 [5][19]. Financial Summary - Revenue projections for FY26 and FY27 have been adjusted to CNY 2.8 billion and CNY 4.8 billion, respectively, reflecting the company's commercialization progress and potential changes in milestone payments [9][21]. - The gross profit margin is expected to improve from 71.9% in FY25 to 77.5% in FY27, indicating enhanced profitability as the company scales its operations [14][21]. - The net profit attributable to the parent is forecasted to be CNY -220 million in FY26 and CNY 820 million in FY27, showing a significant turnaround in profitability [9][21].

Group 1 - The core point of the news is that Rongchang Biopharmaceuticals announced the approval of its self-developed injection drug, Vidisicimab (brand name: Aidiqi), for a new indication in the treatment of specific populations with breast cancer, marking the fourth approved indication for this drug in China [1] - The expansion of indications for Vidisicimab, one of the core products of the company, will further enrich the product matrix and enhance the core competitiveness of the company [1] - The drug has successfully entered the Category B directory through national medical insurance negotiations in 2024, significantly reducing the patient co-payment ratio, which is expected to drive a substantial increase in terminal prescription volume and lay a foundation for market promotion of the new indication [1] Group 2 - Rongchang Biopharmaceuticals' stock price increased by over 4%, with a current price of 90.6 HKD and a trading volume of 67.64 million HKD [2] - The stock performance reflects a rise of 3.82% at the time of reporting, indicating positive market sentiment towards the company's recent developments [2]

Group 1 - Morgan Stanley increased its stake in Innovent Biologics (01801) by acquiring 497,823 shares at a price of HKD 82.2756 per share, totaling approximately HKD 40.9587 million [2] - Following the acquisition, Morgan Stanley's total shareholding in Innovent Biologics reached approximately 87,249,700 shares, representing a 5.02% ownership stake [2]

Group 1 - The core viewpoint of the article highlights the performance and outlook of various companies in different sectors, focusing on their revenue and profit changes in 2025 and early 2026 [5][6][7][8][9] Group 2 - Yun Tianhua (600096.SH) reported a revenue of 48.415 billion yuan in 2025, a decrease of 21.47% year-on-year, with a net profit of 5.156 billion yuan, down 3.40% year-on-year [5] - Xiaopeng Motors (XPEV.N) achieved a total revenue of 76.72 billion yuan in 2025, an increase of 87.7% year-on-year, with a Non-GAAP net loss of 460 million yuan, narrowing by 91.8% year-on-year [5] - Wen Yuan Zhi Xing-W (0800.HK) saw a significant revenue increase to 685 million yuan in 2025, up 89.6% year-on-year, driven by strong sales in robotaxi and related products [6] - Lao Pu Gold (6181.HK) reported a revenue of 27.3 billion yuan in 2025, a year-on-year increase of 221.0%, with a net profit of 4.87 billion yuan, up 230.5% year-on-year [7] - Shede Liquor (600702.SH) experienced a revenue decline to 4.419 billion yuan in 2025, down 17.51% year-on-year, with a net profit of 223 million yuan, down 35.51% year-on-year [8] - China Resources Beer (0291.HK) achieved a revenue of 37.99 billion yuan in 2025, a slight decrease of 1.7% year-on-year, with a net profit of 3.37 billion yuan, down 28.9% year-on-year due to goodwill impairment in the liquor business [8] - Tiantan Biological (600161.SH) continues to focus on innovation and has received a high-tech enterprise certificate, indicating ongoing advancements in product development and a strong market position [9]

香港交易及結算所有限公司、香港聯合交易所有限公司及證券及期貨事務監察委員會對本公告 的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Mabwell (Shanghai) Bioscience Co., Ltd. 邁威（上海）生物科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 警告 本公告乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會 （「證監會」）的要求而刊發，僅用作提供資料予香港公眾人士。 閣下閱覽本公告，即代表 閣下知悉、接納並向本公司、其聯席保薦人、整體協 調人、顧問或包銷團成員表示同意： 1 (a) 在聯交所網站登載本公告，並不引起本公司、其聯席保薦人、整體協調人、 顧問或包銷團成員在香港或任何其他司法權區必須進行發售或配售活動的責 任。本公司最終會否進行發售或配售仍屬未知之數； (b) 本公告所涉及的上市申請並未獲批准，聯交所及證監會或會接納、發回或拒 絕有關的公開發售及╱或上市申請； (c) 本公告不應被視為誘使認購或購買任何證券，亦不擬構成該等 ...

Investment Rating - The report maintains an "Outperform" rating for the company [2][9]. Core Insights - The company achieved a revenue of CNY 2.06 billion in FY25, reflecting a year-on-year growth of 6.5%. Drug sales revenue was CNY 540 million, while licensing and collaboration income decreased by 20% to CNY 1.50 billion. The net loss for the year was CNY 380 million, compared to a loss of CNY 270 million in FY24 [3][16]. - Several products have been successfully commercialized in China, including sac-TMT, tagitanlimab, cetuximab N01, and trastuzumab botidotin, with the first three included in the National Reimbursement Drug List (NRDL). The NDA for lenvatinib fumarate has been submitted, with commercialization expected to start in 2027 [4][17]. - The company is progressing well in its clinical trials, with sac-TMT approved for multiple indications in China and 17 global Phase 3 trials initiated by Merck. Key data readouts are anticipated in 2026 and 2027 [5][19][23]. Financial Summary - Revenue projections for FY26 and FY27 have been adjusted to CNY 2.8 billion and CNY 4.8 billion, respectively, reflecting the company's commercialization progress. The net profit attributable to the parent is forecasted to be CNY -220 million in FY26 and CNY 820 million in FY27 [9][21]. - The gross profit margin is expected to improve from 71.9% in FY25 to 77.5% in FY27, indicating enhanced operational efficiency [14].

Investment Rating - The report suggests a positive outlook for the company, indicating that it is significantly undervalued with a market capitalization of only 2.7 billion HKD, and recommends active monitoring of the stock [9]. Core Insights - The company achieved a total revenue of 0.29 billion RMB for the fiscal year 2025, representing a year-on-year growth of 1344.77%, while net losses narrowed by 43.27% to 1.05 billion RMB [1]. - Cost control measures have been effective, with administrative expenses reduced by 16.4 million RMB and R&D costs optimized, particularly focusing on the SM17 clinical trials [2]. - The clinical development of SM17 is progressing rapidly, with promising results in the 1b phase study for atopic dermatitis, showing a 91.7% itch relief rate and 75% achieving skin lesion recovery [3]. - The company is building a differentiated pipeline in autoimmune diseases, with potential for significant business development (BD) opportunities as clinical trials advance [4]. Summary by Sections Financial Performance - Total revenue for 2025 reached 0.29 billion RMB, a substantial increase of 1344.77% year-on-year, while net losses decreased to 1.05 billion RMB, a reduction of 43.27% compared to the previous year [1]. Cost Management - The company has effectively controlled costs, reducing administrative expenses by 16.4 million RMB and optimizing R&D costs, particularly in the SM17 clinical program [2]. Clinical Development - SM17 is advancing quickly in clinical trials, with a 2nd phase study for atopic dermatitis expected to start in mid-2026, and positive results from the 1b phase study indicating high efficacy and safety compared to existing treatments [3]. Pipeline and Strategic Focus - The company is focused on developing first-in-class (FIC) and best-in-class (BIC) therapies, with a rich pipeline in autoimmune diseases and plans for significant BD opportunities as key data is released in 2026-2027 [4].